These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24606321)

  • 21. Plasma galectin-3 as a biomarker for clinical staging of heart failure: a cross-sectional evaluation of 100 cases.
    Gocer H; Günday M; Ünal M
    Clin Ter; 2019; 170(4):e267-e271. PubMed ID: 31304514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Galectin-3 and heart failure: prognosis, prediction & clinical utility.
    Filipe MD; Meijers WC; Rogier van der Velde A; de Boer RA
    Clin Chim Acta; 2015 Mar; 443():48-56. PubMed ID: 25446877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of galectin-3 in patients with heart failure.
    Bošnjak I; Selthofer-Relatić K; Včev A
    Dis Markers; 2015; 2015():690205. PubMed ID: 25960597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Galectin 3--a new biomarker for diagnostics and outcome of chronic heart failure].
    Lakomkin SV; Skvortsov AA; Goriunova TV; Masenko VP; Tereshchenko SN
    Kardiologiia; 2012; 52(3):45-52. PubMed ID: 22839443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serial galectin-3 and future cardiovascular disease in the general population.
    van der Velde AR; Meijers WC; Ho JE; Brouwers FP; Rienstra M; Bakker SJ; Muller Kobold AC; van Veldhuisen DJ; van Gilst WH; van der Harst P; de Boer RA
    Heart; 2016 Jul; 102(14):1134-41. PubMed ID: 27084804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).
    Gullestad L; Ueland T; Kjekshus J; Nymo SH; Hulthe J; Muntendam P; McMurray JJ; Wikstrand J; Aukrust P
    Am Heart J; 2012 Dec; 164(6):878-83. PubMed ID: 23194488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pilot study to demonstrate diagnostic potential of galectin-3 levels in saliva.
    Zhang X; Wan Y; Chata R; Brazzale A; Atherton JJ; Kostner K; Dimeski G; Punyadeera C
    J Clin Pathol; 2016 Dec; 69(12):1100-1104. PubMed ID: 27340130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Galectin-3 is associated with severe heart failure and death: A hospital-based study in Chinese patients.
    Wang N; Dang M; Zhang W; Lei Y; Liu Z
    Scand J Immunol; 2020 May; 91(5):e12826. PubMed ID: 31514240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Personalizing biomarker strategies in heart failure with galectin-3.
    Sherwi N; Merali S; Wong K
    Future Cardiol; 2012 Nov; 8(6):885-94. PubMed ID: 23176690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The fibrosis marker galectin-3 and outcome in the general population.
    de Boer RA; van Veldhuisen DJ; Gansevoort RT; Muller Kobold AC; van Gilst WH; Hillege HL; Bakker SJ; van der Harst P
    J Intern Med; 2012 Jul; 272(1):55-64. PubMed ID: 22026577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. State of the Art: Newer biomarkers in heart failure.
    de Boer RA; Daniels LB; Maisel AS; Januzzi JL
    Eur J Heart Fail; 2015 Jun; 17(6):559-69. PubMed ID: 25880523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The emerging role of Galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers.
    Karayannis G; Triposkiadis F; Skoularigis J; Georgoulias P; Butler J; Giamouzis G
    Curr Heart Fail Rep; 2013 Dec; 10(4):441-9. PubMed ID: 24142671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Immunoanalytical characteristics of galectin-3].
    Desbène C; Gaillard O
    Ann Biol Clin (Paris); 2014; 72(4):491-9. PubMed ID: 25119810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).
    Gullestad L; Ueland T; Kjekshus J; Nymo SH; Hulthe J; Muntendam P; Adourian A; Böhm M; van Veldhuisen DJ; Komajda M; Cleland JG; Wikstrand J; McMurray JJ; Aukrust P;
    Eur Heart J; 2012 Sep; 33(18):2290-6. PubMed ID: 22513778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Value of Galectin-3 assay in children with heart failure secondary to congenital heart diseases: a prospective study.
    Saleh N; Khattab A; Rizk M; Salem S; Abo-Haded H
    BMC Pediatr; 2020 Nov; 20(1):537. PubMed ID: 33248453
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meta-Analysis of the Usefulness of Plasma Galectin-3 to Predict the Risk of Mortality in Patients With Heart Failure and in the General Population.
    Imran TF; Shin HJ; Mathenge N; Wang F; Kim B; Joseph J; Gaziano JM; Djoussé L
    Am J Cardiol; 2017 Jan; 119(1):57-64. PubMed ID: 28247849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Galectin-3 and the Mineralocorticoid Receptor Antagonist Canrenone in Mild Heart Failure.
    Clemenza F; Masson S; Conaldi PG; Di Carlo D; Boccanelli A; Mureddu GF; Gonzini L; Lucci D; Maggioni AP; Di Lenarda A; Nicolis EB; Vanasia M; Latini R;
    Circ J; 2017 Sep; 81(10):1543-1546. PubMed ID: 28855452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis.
    Meijers WC; van der Velde AR; Ruifrok WP; Schroten NF; Dokter MM; Damman K; Assa S; Franssen CF; Gansevoort RT; van Gilst WH; Silljé HH; de Boer RA
    J Am Heart Assoc; 2014 Sep; 3(5):e000962. PubMed ID: 25237044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease.
    Tuñón J; Blanco-Colio L; Cristóbal C; Tarín N; Higueras J; Huelmos A; Alonso J; Egido J; Asensio D; Lorenzo Ó; Mahíllo-Fernández I; Rodríguez-Artalejo F; Farré J; Martín-Ventura JL; López-Bescós L
    Am J Cardiol; 2014 Feb; 113(3):434-40. PubMed ID: 24295549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices.
    Milting H; Ellinghaus P; Seewald M; Cakar H; Bohms B; Kassner A; Körfer R; Klein M; Krahn T; Kruska L; El Banayosy A; Kramer F
    J Heart Lung Transplant; 2008 Jun; 27(6):589-96. PubMed ID: 18503956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.